The proposed bill, known as the Pharmacists Test-and-Treat Authority Act, aims to enhance public health by authorizing licensed pharmacists to independently test for and initiate treatment of certain conditions. The bill establishes a new chapter in the General Laws that outlines the authority of pharmacists to provide test-and-treat services, which includes ordering, performing, and interpreting CLIA-waived tests, as well as initiating, dispensing, administering, or prescribing medications. The Board of Pharmacy, in consultation with the Department of Health, will develop statewide protocols for the conditions that pharmacists can treat, which may include influenza, COVID-19, group A streptococcal pharyngitis, and post-exposure prophylaxis for sexually transmitted infections.

Additionally, the bill mandates that health insurance carriers provide coverage for the services rendered by pharmacists within their lawful scope of practice, effective January 1, 2027. It specifies that no health insurance provider may require supervision, signature, or referral from another healthcare provider as a condition of reimbursement to a pharmacist, ensuring that patients have direct access to these services. The legislation also includes provisions for training and competency requirements for pharmacists providing these services, as well as documentation and communication requirements to ensure continuity of care.